Chemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafish
Author(s) -
David Kokel,
Randall T. Peterson
Publication year - 2008
Publication title -
briefings in functional genomics and proteomics
Language(s) - English
Resource type - Journals
eISSN - 1477-4062
pISSN - 1473-9550
DOI - 10.1093/bfgp/eln040
Subject(s) - phenomics , zebrafish , drug discovery , biology , neuroscience , neuropharmacology , bioinformatics , genetics , genomics , genome , gene
Despite their ubiquity and impact, psychiatric illnesses and other disorders of the central nervous system remain among the most poorly treated diseases. Most psychiatric medicines were discovered due to serendipitous observations of behavioural phenotypes in humans, rodents and other mammals. Extensive behaviour-based chemical screens would likely identify novel psychiatric drugs. However, large-scale chemical screens in mammals are inefficient and impractical. In contrast, zebrafish are very well suited for high-throughput behaviour-based drug discovery. Furthermore, the vast amounts of data generated from large-scale behavioural screens in zebrafish will facilitate a systems-level analysis of how chemicals affect behaviour. Unlike serendipitous discoveries in mammals, a comprehensive and integrative analysis of zebrafish chemobehavioural phenomics may identify functional relationships that would be missed by more reductionist approaches. Thus, behaviour-based chemical screens in the zebrafish may improve our understanding of neurobiology and accelerate the pace of psychiatric drug discovery.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom